In addition, OncoVEXmGM-CSF (T-VEC with mouse GM-CSF) demonstrated preclinical efficacy in increasing tumor-specific CD8+ T-cell and systemic efficacy in tumor cells when combined with a checkpoint blockade in murine mouse models [31,32]. The gene discussed is CD8A; the disease is neoplasm.